We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer

By LabMedica International staff writers
Posted on 05 Feb 2024
Print article
Image: The DxC 500 AU chemistry analyzer unveiled at Medlab Middle East 2024 (Photo courtesy of Beckman Coulter)
Image: The DxC 500 AU chemistry analyzer unveiled at Medlab Middle East 2024 (Photo courtesy of Beckman Coulter)

Beckman Coulter Diagnostics (Brea, CA, USA) is unveiling the new DxC 500 AU, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai, taking place February 5-8, 2024. The DxC 500 AU chemistry analyzer is one of several recent solutions designed by the company to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories.

The DxC 500 AU chemistry analyzer features advanced automation technology, onboard guided workflows, and standardized reagents for use across healthcare networks. Its menu of more than 120 assays has been independently and objectively verified for high-quality Six Sigma performance, supporting confidence in clinical results, and reducing QC troubleshooting and lab operational costs. The DxC 500 AU chemistry analyzer is for in vitro diagnostic use only and is available throughout North America and the Middle East with global commercial availability planned for March 2024.

"Healthcare systems around the world are strategically adopting hub-and-spoke models for better efficiency and healthcare access," said Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics. "Hub-and-spoke clinical laboratory models optimize resources to improve access to testing services and enhance overall standardization for quality testing and positive impact on inventory and cost management across a health system. The new DxC 500 AU Chemistry Analyzer advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter's AU clinical chemistry systems, positively impacting clinical decision-making and patient outcomes."

Related Links:
Beckman Coulter Diagnostics

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Cryptosporidium Infection Test
Crypto (Card) Rapid Test
New
Nephelometer
F-TC2015

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
MEDLAB 2024
Copyright © 2000-2025 Globetech Media. All rights reserved.